Quick Answer
Vor Biopharma Inc. reported Research And Development Expense of $321.53 million for the year ending 2025.
- Vor Biopharma Inc. showed an increase of +244.6% in Research And Development Expense from 2024 to 2025.
- This data is from Vor Biopharma Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $6.17 million | Q2 2020: $5.98 million | Q3 2020: $8.14 million | Q1 2021: $8.94 million | Q2 2021: $12.97 million | Q3 2021: $12.93 million | Q1 2022: $15.28 million | Q2 2022: $15.33 million | Q3 2022: $16.88 million | Q1 2023: $21.92 million | Q2 2023: $23.90 million | Q3 2023: $27.61 million | Q1 2024: $24.32 million | Q2 2024: $21.82 million | Q3 2024: $21.82 million | Q1 2025: $26.70 million | Q2 2025: $261.50 million | Q3 2025: $14.14 million.
- Over the full 6 years of available data (2020 to 2025), Vor Biopharma Inc.'s Research And Development Expense has grown by 916.9%.
- Historical annual values: Fiscal year 2025: $321.53 million | Fiscal year 2024: $93.31 million | Fiscal year 2023: $94.32 million | Fiscal year 2022: $64.55 million | Fiscal year 2021: $47.53 million | Fiscal year 2020: $31.62 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: